rss
J Clin Pathol 2003;56:666-671 doi:10.1136/jcp.56.9.666
  • Original article

Expression of smooth muscle markers in so called malignant fibrous histiocytomas

  1. T Hasegawa1,
  2. F Hasegawa2,
  3. T Hirose3,
  4. T Sano4,
  5. Y Matsuno5
  1. 1Pathology Division, National Cancer Centre Research Institute, 5–1–1 Tsukiji, Chuo-ku, Tokyo 104–0045, Japan
  2. 2Electron Microscopy Laboratory, National Cancer Centre Research Institute
  3. 3Department of Pathology, Saitama Medical School, Saitama, Japan
  4. 4Department of Pathology, University of Tokushima School of Medicine, Japan
  5. 5Clinical Laboratory Division, National Cancer Centre Hospital, Tokyo, Japan
  1. Correspondence to:
 Dr T Hasegawa, Pathology Division, National Cancer Centre Research Institute, 5–1–1 Tsukiji, Chuo-ku, Tokyo 104–0045, Japan;
 tdhasega{at}ncc.go.jp
  • Accepted 28 March 2003

Abstract

Aims: To obtain further information regarding the frequency and degree of positivity for smooth muscle markers in a large number of malignant fibrous histiocytomas (MFHs), as an aid to accurate diagnosis.

Method: The immunohistochemical features of 100 MFHs were studied and the results were compared with those for 30 leiomyosarcomas. Eighteen cases of MFH with smooth muscle actin (SMA) positivity were examined ultrastructurally.

Results: Immunoreactivity for smooth muscle markers, such as desmin, SMA, muscle specific actin (MSA) and h-caldesmon (HCD), which is a specific marker for smooth muscle cells and their tumours, was found in 28, 30, 29, and 29 of 30 leiomyosarcomas. Immunoreactivity for desmin, SMA, MSA, and HCD was found in 17, 30, 14, and two of the MFHs. On electron microscopic examination, approximately half of the cases contained a varying proportion of myofibroblastic cells. The others had only fibroblastic or undifferentiated tumour cells. At least 30% of the cases were found to display features consistent with limited smooth muscle or myofibroblastic differentiation.

Conclusion: A large subset of so called MFH in fact shows poorly differentiated smooth muscle or myofibroblastic features, and perhaps such tumours should be regarded as pleomorphic leiomyosarcomas and/or pleomorphic myofibroblastic sarcomas.

Footnotes

    Responses to this article

    • Author's reply to Zardawi
      • Tadashi Hasegawa
      J Clin Pathol published online December 17, 2003
    • Re: Expression of smooth muscle markers in so called malignant fibrous histiocytoma
      • Ibrahim M Zardawi
      J Clin Pathol published online November 24, 2003

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.